Table 2.
Comparison small bowel inactive and active in colonic inactive group
| Small bowel inactive (n = 11) | Small bowel active (n = 11) | p value | ||
|---|---|---|---|---|
| Age (years) | median (IQR) | 16.3 (15.8–18.3) | 12.8 (11.2–15.1) | 0.006** |
| Male/Female | 11/0 | 11/0 | 0.317 | |
| Body mass index (kg/m2) | mean ± SD | 20.2 ± 2.2 | 20.8 ± 3.7 | 0.922 |
| Growth height z-score | mean ± SD | –1.4 ± 2.2 | –2.1 ± 2.0 | 0.577 |
| C-reactive protein (mg/dl) | median (IQR) | 0.03 (0.02–0.05) | 0.09 (0.07–0.39) | 0.007** |
| ESR (mm/1 h) | median (IQR) | 3.0 (2.0–5.0) | 8.0 (4.0–11.0) | 0.003** |
| Albumin (g/dl) | mean ± SD | 4.7 ± 0.4 | 4.3 ± 0.3 | 0.019* |
| Fecal hemoglobin (ng/ml) | mean ± SD | 0.0 ± 0.0 | 81.6 ± 258.0 | 0.294 |
| Fecal calprotectin (µg/g) | median (IQR) | 98 (47–224) | 826 (488–1,235) | 0.001** |
| PCDAI | median (IQR) | 5.0 (0.0–5.0) | 0 (0–20.0) | 0.777 |
| Treatment | ||||
| 5-ASA | 100% (11/11) | 72.7% (8/11) | 0.069 | |
| Azathioprine (or 6-mercaptopurine) | 45.5% (5/11) | 63.6% (7/11) | 0.403 | |
| Infliximab | 54.5% (6/11) | 0% (0/11) | 0.005** | |
| Others (no medication or herbal medicine) | 0% (0/11) | 27.3% (3/11) | 0.069 |
Asterisks represent significant difference and abbreviations are referred following. ESR, erythrocyte sedimentation rate; PCDAI, Pediatric Crohn’s Disease Activity Index (clinical remission; <10); 5-ASA, 5-aminosalicylic acid.